Hsieh Evelyn (Orcid ID: 0000-0001-5018-8409)
Dey Dzifa (Orcid ID: 0000-0002-3339-5112)
Grainger Rebecca (Orcid ID: 0000-0001-9201-8678)
Li Mengtao (Orcid ID: 0000-0003-4252-2889)
Machado Pedro M. (Orcid ID: 0000-0002-8411-7972)
Ugarte-Gil Manuel Francisco (Orcid ID: 0000-0003-1728-1999)
Yazdany Jinoos (Orcid ID: 0000-0002-3508-4094)

Global Perspective on the Impact of the COVID-19 Pandemic on Rheumatology and Health Equity

Evelyn Hsieh, MD, PhD[1,2]; Dzifa Dey, FRCP, FWACP, FGCP, MSc[3]; Rebecca Grainger, MBChB (Dstn), BMedSci (Dstn),FRACP, PhD[4]; Mengtao Li, MD[5]; Pedro M. Machado, MD, PhD[6,7,8]; Manuel F. Ugarte-Gil MD, MSc[9,10] Jinoos Yazdany, MD, MPH[11]

Running Title: Global Impact of COVID-19 on Rheumatology and Health Equity

Affiliations:

[1] Section of Rheumatology, Allergy & Immunology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

[2] Section of Rheumatology, Department of Internal Medicine, VA Connecticut Healthcare System, West Haven, CT, USA

[3] Rheumatology Unit, Department of Medicine and Therapeutics, Korle-bu Teaching Hospital, University of Ghana Medical School, Accra, Ghana

[4] Department of Medicine, University of Otago, Wellington, New Zealand

[5] Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/acr.25169

College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China

[6] Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK

[7] National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK

[8] Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK

[9] Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémica, Universidad Científica del Sur, Lima, Perú

[10] Rheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Perú

[11] Division of Rheumatology, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA.

Key Words: COVID-19, global health, rheumatic diseases, health equity

Word Count: 4657

Disclosures: D.D. has received consulting/speaking fees from Roche and Janssen all unrelated to this manuscript. R.G. has received consulting/speaking fees from AbbVie, GSK, Janssen, Novartis and Cornerstones, all unrelated to this manuscript. M.L. has received speaking fees and/or honoraria from GlaxoSmithKline, MSD, Pfizer, and Janssen Pharmaceuticals. P.M.M. has received consulting/speaker's fees from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript, and is supported by the National Institute for Health Research (NIHR), University College London Hospitals (UCLH), Biomedical Research Centre (BRC). M.U. has received consulting/speaking fees from Aztra-Zeneca and GSK, and grant support from Pfizer and Janssen all unrelated to this manuscript. J.Y. has received grant support from Gilead, AstraZeneca, and Aurinia and performed consulting for AstraZeneca, all unrelated to this manuscript.

Correspondence:

Evelyn Hsieh, MD, PhD

Associate Professor of Medicine (Rheumatology, Allergy & Immunology), Yale School of Medicine, New Haven, CT, USA; Associate Professor of Chronic Disease Epidemiology, Yale School of Public Health; Chief of Rheumatology, VA Connecticut Healthcare System, West Haven, CT, USA.

Email: evelyn.hsieh@yale.edu

Jinoos Yazdany, MD, MPH

Alice Betts Endowed Professor of Medicine, Division of Rheumatology, University of California, San Francisco, Chief of Rheumatology at Zuckerberg San Francisco General Hospital, San Francisco, CA, USA.

Email: jinoos.yazdany@ucsf.edu

ABSTRACT

Although the public health emergency associated with the COVID-19 pandemic has ended, challenges remain, especially for individuals with rheumatic diseases. We aimed to assess the historical and ongoing effects of COVID-19 on people with rheumatic diseases and rheumatology practices globally, with specific attention to vulnerable communities and lessons learned. We reviewed literature from several countries and regions, including Africa, Australia and New Zealand, China, Europe, Latin America, and the United States. We summarize literature that not only examines the impact of the pandemic on people with rheumatic diseases, but also research that reports the lasting changes to rheumatology patient care and practice, and on health service use. Across countries, challenges faced by people with rheumatic diseases during the pandemic included disruptions in healthcare and medication supply shortages. These challenges were associated with worse disease and mental health outcomes in some studies, particularly among those who had social vulnerabilities defined by socioeconomic, race, or rurality. Moreover, rheumatology practice was impacted in all regions, with the uptake of telemedicine and changes in healthcare utilization. While many regions developed rapid guidelines to disseminate scientific information, misinformation and disinformation remained widespread. Finally, vaccine uptake among people with rheumatic diseases has been uneven across the world. As the acute phase of the pandemic wanes, ongoing efforts are needed to improve healthcare access, stabilize rheumatology drug supplies, improve public health communication, and implement evidence-based vaccination practices to reduce COVID-19 morbidity and mortality among people with rheumatic diseases.

INTRODUCTION

The COVID-19 pandemic created significant challenges for people with rheumatic diseases, particularly for vulnerable populations. Challenges included maldistribution of testing and vaccines, unequal access to healthcare, and more severe outcomes of infection, all of which have disproportionately affected people with low socioeconomic status. The pandemic has also exposed disparities in health and healthcare that already existed in many countries, highlighting the need for both local and global responses to address differential outcomes in populations at higher risk of severe COVID-19.

Three years into the pandemic, it is important to reflect on the impact of COVID-19 on both people with rheumatic disease and on rheumatology practice. In this paper, a global team of rheumatologists reviewed the literature on the impacts of COVID-19 in rheumatology in several countries and regions, including Africa, Australia/New Zealand, China, Europe, Latin America, and the United States. Where possible, we focused our literature review specifically on people from socioeconomic, racial, or ethnic groups with historically fewer resources and access to care, indigenous populations, and rural populations. We summarize literature that not only examines the impact of the pandemic on these populations, but also research that reports the lasting changes to rheumatology patient care and practice, and on health service use.

By providing this synthesis of the literature, we aim to identify lessons learned which the global rheumatology community can apply to improve care for people with rheumatic diseases.

AFRICA

The earlier public health experts' forecasts of COVID-19 pandemic impact projected a bleak image for Africa [1]. Health systems in the continent were described as having varied and less preparedness compared to other parts of the world, hence the region was anticipated to suffer a disproportionate burden of disease and death. Fortunately, these predictions did not pan out as fewer deaths than expected have been reported on the continent. The pandemic nevertheless had dire consequences on the socio-economic and political landscape, and health systems of Africa [2,3].

Impact on patients. The impact of the pandemic on people with rheumatic disease has been profound, including disruptions in access to care, shortages of drugs, and a rise in self-reported mental health issues. Several African studies have sought to quantify some of the associated burden. In a regional study to determine the impact of COVID-19 on people with chronic rheumatic diseases, the pandemic negatively impacted rheumatology visits (82% of cases), availability of hydroxychloroquine (47%), and mental health (73%) [4].

The African League of Associations of Rheumatology (AFLAR) reported an acute shortage of hydroxychloroquine, noted by seven out of ten rheumatologists, and one out of five had to lower the amounts they prescribed to patients to make the supply last [5]. A retrospective study of 342 South Africans patients receiving care at an academic rheumatology center reported 80% had interruptions in chloroquine access and 69 patients experienced a physician-determined disease flare [6].

Other data suggest negative impacts on disease control and quality of life in patients in Africa. A study of patients with rheumatoid arthritis (RA) from a single center in Benin reported mean (+/- SD) DAS-28 scores increasing from 3.4±1.5 pre-pandemic to 4.7+/-2.04 in May 2020. Quality of life decreased also with the physical (PCS) and mental (MCS) components scores of the MOS-SF36 measured as 71.1±20.3 and 67.1±16.02 pre-pandemic to 38.1±4.96 and 36.8±3.8, respectively [7].

Among an Egyptian rheumatic disease group, patients were found to be more vulnerable to mental health disorders and psychological distress, with 49%, 29% and 1% of patients having experienced moderate, severe and extremely severe anxiety, respectively, as a result of COVID-19 [8].

Impact on Health Care Providers and Practice. The pandemic has pushed many rheumatology clinics across Africa to adopt more virtual consultations (telemedicine), with significant reductions in daily hospital activities such as infusions and other outpatient activities; these changes have also corresponded to significant negative impacts on mental health being reported by rheumatologists [9,10].

One of the most remarkable efforts to respond to challenges and uncertainties created by COVID-19 in rheumatology practice in Africa was the formation of a special task force that aimed to develop recommendations for the management of rheumatic disease patients during the pandemic [11]. A Pan African survey on experiences of rheumatologists provided comprehensive insight into the rheumatology service organization and the extent of service disruption caused by the COVID-19 pandemic [5,12]

Vaccination has presented another major challenge in Africa. There has been a high level of skepticism and hesitancy towards vaccination [13]. These data show a reluctance across the whole population towards receiving COVID-19 vaccines, though this improved over time. Some governments in Africa prioritized patients with rheumatic diseases for COVID-19 vaccination. In South Africa, patients with comorbidities, including RA, were included in the second phase of the national vaccination program [14]. In Nigeria, individuals with underlying medical conditions, including rheumatic diseases, were in the priority group for vaccination [15]. Unlike other parts of the world, not much has been done to look at antibody response in rheumatic patients. In Egypt and Morocco, it was found that there was lower antibody responses to the Sinopharm vaccine and Sinovac vaccines among the normal population and health workers [16,17].

Lessons Learned. In Africa, priorities include patient and population education regarding vaccination and mental health support. The health system could benefit from ongoing medical education for doctors, advocacy for rheumatology, access to drugs (biologics and hydroxychloroquine), an accessible telemedicine platform, more organized rheumatology units, and adequate supplies of personal protective equipment (PPE); these are among the top-cited unmet needs to deal with rheumatic diseases in Africa in the wake of the COVID-19 pandemic.

CHINA

As the first country heavily struck by the COVID-19 outbreak, China adopted a series of policies to contain virus spread including lockdown, a strict zero-COVID policy, mobilization of resources, vaccination, and drug development. These policies, which were in place through December 2022, were intended to spare no efforts to reduce mortality and protect vulnerable populations such as the elderly and patients with chronic diseases including rheumatic diseases and were largely successful from the perspective of mitigating COVID-19-related outcomes.

Impact on patients. In China, the impact of COVID-19 on people with rheumatic diseases has been multi-faceted, including less access to routine healthcare, increased risk of infection and severe disease, and concerns about vaccination. Several studies have evaluated how COVID-19 has influenced clinical outcomes (e.g., frequency of infections or flares), health-related concerns and behaviors (e.g., vaccination-related concerns and uptake), and changes in access to care for patients with rheumatic diseases since the emergence of the pandemic. For example, a number of retrospective studies in Wuhan – the capital of Hubei Province, and the first city in China impacted by the COVID-19 pandemic in early 2020 – reported outcomes of patients with rheumatic diseases [18–21]. Similar to findings from other regions, patients with rheumatic diseases in China were found to be more susceptible to COVID-19 infection than the general population [21]. Rheumatic diseases were also shown to aggravate the course of infection [18] and increase the risk of respiratory failure [19]. However, additional data including those from studies outside of Wuhan, found that with adequate medical intervention in China, COVID-19 was not necessarily associated with increased likelihood of critical outcomes such as ICU occupancy [22], mechanical ventilation [21] and fatality [18]. Based on these findings, national rheumatology associations in China and APLAR have published recommendations to improve the outcomes of COVID-19 in rheumatic patients [23].

Impact on Health Care Providers and Practice. The COVID-19 pandemic had a substantial impact on the long-term follow-up of patients with rheumatic disease in China. Early and intensive measures were adopted to contain COVID-19 with strict mask mandates, social distancing and routine testing requirements, and swift lockdowns coupled with contact tracing when cases were identified. While these measures disrupted in-person care for many patients with rheumatic disease, they were also viewed as an effective means to protect vulnerable populations from COVID-19 [24]. In response, the use of telemedicine in rheumatology care was rapidly and significantly expanded in China [25,26].

Despite the availability of vaccines, COVID-19 vaccination rates in Asian countries, including China, remain low [27]. Other than the mRNA and adenovirus vector vaccines used in western countries, inactivated COVID-19 vaccines were widely used in China. The efficacy and safety of these vaccines have been confirmed [28]. Although more research is needed, some data suggest that patients may experience disease flare after vaccination [28]. A nationwide, multicenter survey conducted to investigate vaccination-related concerns in Chinese patients with rheumatic diseases found that concerns regarding adverse effects and disease flare were the main factors affecting vaccination willingness [29]. Recommendations have been published in China to address vaccine hesitancy [30].

Lessons Learned. There are some key lessons learned from the management of patients with rheumatic diseases during the COVID-19 pandemic. First, policies for early intensive methods against spread of infection play an important role in the protection of vulnerable populations who are at higher risk of infection and severe outcomes. Second, patients with chronic disease may have less access to routine healthcare due to restriction of traveling to avoid infection, which may further result in poor monitoring, delayed adjustment of treatment regimens and excessive risk of flare. Thus, the expansion of telemedicine has been a welcome innovation. Third, better understanding of patients' concerns and more individualized education are required to improve vaccination rates among these vulnerable populations. Proper guidance [31] for patients is not only the duty of rheumatologists, but also requires collaborative efforts from the social media and government.

AUSTRALIA AND NEW ZEALAND

Both Australia and Aotearoa New Zealand adopted "zero-COVID" suppression/elimination strategies. In March 2020 these island states, along with most in Oceania, established strict border control with quarantine after entry. Both countries had comprehensive testing and case isolation systems and implemented social distancing measures with lockdowns when community transmission occurred. National COVID-19 vaccination programmes began in 2021, obtaining high levels of vaccination by late 2021. New Zealand avoided widespread community transmission of COVID-19 until 2022 and can report the overall best mortality protection outcomes among countries in the Organization for Economic Co-operation and Development (OECD), and performed better than OECD average economically [32]. Australia controlled a significant outbreak in Melbourne in late 2020 that particularly impacted older adults in aged residential care, then continued with a zero-COVID strategy until mid-2021 [33]. These approaches have been successful but with some areas for improvement [34].

Impact on patients. Given largely successful early COVID-19 containment strategies, people with rheumatic disease were able to reduce risk of exposure comparatively easily. There were also long periods in 2020 and 2021 when there was no COVID-19 transmission, and in-person health services were not disrupted. During periods of required physical distancing, most ambulatory rheumatology care was moved to virtual care, often via telephone [35]. In Australia people with rheumatic disease reported high confidence in accessing health care, with high acceptability for telemedicine-delivered care reported early in the pandemic [36,37]. While there were short-lived restrictions on hydroxychloroquine dispensing, supplies were not interrupted. Tocilizumab became unavailable for rheumatic disease indications in both countries, forcing changes to treatment for those relying on this medication. In New Zealand this resulted in the first government subsidization of Janus kinase inhibitors in late 2021. Australia implemented rapid changes in funding authorization of advanced therapies to ensure continuity of care. Overall, there were some changes and delays to patient care but most were managed proactively.

While there is not yet published data on COVID-19 outcomes for people with rheumatic disease in Australasia, it seems likely that patterns will follow those seen in other high-income countries with high rates of vaccination. Population data shows older persons and some ethnic groups experienced high rates of poor outcomes from COVID-19 [38] with Māori and Pacific peoples experiencing higher rates of COVID-19 infections, in part due to inequitable delivery of public health measures such as contact tracing [39].

Impact of healthcare providers and practice. There were however negative impacts on patient care delivery at times during the pandemic. Data from two retrospective studies involving medical record review in single centers with telephone-based care during the initial lockdowns of 2020 reported no decrease in service volumes but lower frequency of change in rheumatic disease medications [40,41]. Diagnosis was more often deferred and high rates of earlier than expected follow up appointments were also noted (10, Zhu 2021). In 2023, both countries are moving towards managing COVID-19 as an endemic infection. Rheumatology care has largely returned to pre-pandemic patterns. Australian rheumatology practices had been early adopters of telemedicine to meet needs of a geographically dispersed rural population and to extend the reach of a limited rheumatology workforce [42]. In Queensland, a state seven-times the size of Great Britain, three quarters of rheumatologists had used telemedicine before the pandemic, mostly with a hub model of a healthcare provider located with the patient [43]. During the pandemic, rheumatologists had a low confidence in telephone-based rheumatology care delivery and anticipated ongoing barriers to telemedicine adoption including quality of care, efficiency and reimbursement [43]. Some practices have been more successful in incorporating virtual care into ongoing rheumatology practice [44].

Lessons Learned. The bold public health approaches of the Australian and New Zealand governments have led to lower COVID-19 health burden and maintained economic activity. While data on health and other outcomes for people with rheumatic disease are awaited, we anticipate these to be favorable also. Underpinnings that enabled these outcomes included universal healthcare access and strong public trust in government processes.

EUROPE

The COVID-19 pandemic has transformed rheumatology healthcare delivery in Europe. The pandemic is likely to have had detrimental effects on patient management and quality of care, despite the efforts and teamwork displayed by the rheumatology community in its worldwide and integrated response.

Impact on patients. An online survey of 1,800 patients conducted at the start of the pandemic revealed that 58% had their rheumatology appointments canceled and 46% were not given any information about how SARS-CoV-2 infection might affect their rheumatic disease and treatment. In addition, 46% were unable to continue exercising regularly, 25% increased smoking, and 18% increased alcohol consumption. Based on scores on the Hospital Anxiety and Depression Scale (HADS), 46% had depression and 58% were at risk for anxiety. Half of the patients reported poor well-being [45].

Inequalities in COVID-19 mortality still exist. The Health Foundation, an independent charitable organization in the UK, reports mortality rates are 3 to 4 times higher in the poorest areas. However, compared to the first year of the pandemic, the overall number of COVID-19 deaths is now significantly lower. Vaccination programs have played a key role in reducing COVID-19 mortality, but for some populations, uptake is still low, particularly for people living in poorer areas and people from some minority ethnic groups [46].

Impact on healthcare providers and practice. A Europe-wide survey of 1,286 rheumatologists from 35 countries revealed that over 80% canceled or postponed face-to-face visits with new patients, and 91% did the same for follow-up visits. Treatment choices were frequently delayed, and over 70% were hesitant to prescribe biological/targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) during the early stages of the pandemic, primarily due to patient anxiety, scarcity of screening tools, and decline in the availability of rheumatological services. This is a missed opportunity for the best patient care [47]. Variations were observed among countries due to the pandemic's impact, response strategies, and telemedicine regulations [48]. From the perspective of training, in a survey of 302 rheumatology trainees (30% from Europe, 38% from the USA, and 32% from other countries), a negative impact of the pandemic on learning opportunities during rheumatology training, including outpatient clinics (79%), inpatient consultations (59%), didactic teaching (55%), procedures (53%), teaching opportunities (52%) and ultrasonography (36%) was reported. Moreover, 39% of trainees reported that COVID-19 negatively affected their ability to continue their pre-pandemic research [49].

Additional reports have suggested that COVID-19-related issues, such as prioritization of COVID-19 research, redeployment of research staff, and the requirement for social distancing, have had a negative impact on the recruitment of participants to non-COVID-19-related research [50]. According to a survey of over 1,000 people with rheumatic diseases, patients' willingness to participate in research during the pandemic also decreased. Respondents were less likely to participate in observational or interventional research studies during COVID-19 compared to before the pandemic (86% vs. 64% and 61% vs. 44%, respectively) [51].

The management of rheumatic diseases within the context of COVID has been addressed by overarching European institutions, such as the European Alliance of Associations for Rheumatology (EULAR). EULAR monitored the published literature and provided recommendations on the risk and prognosis of SARS-CoV-2 infection as well as the safety and efficacy of vaccination against SARS-CoV-2 in patients with rheumatic diseases [52–55].

Lessons Learned. Repercussions of COVID-19 were vast and are far from over, and we will need to continue addressing its long-term impacts. Omicron has become the most prominent variant, leading to less severe infections, and resulting in a decrease in COVID-19 public concern. However, the long-term sequelae of COVID-19, commonly referred to as long-COVID, continue to affect millions of people in Europe and worldwide [48]. It remains unclear whether long-COVID is more frequent in people with rheumatic diseases and further studies are warranted. New questions are now being raised since most people with rheumatic diseases have received at least one complete vaccination cycle and a booster. There appears to be significant individual variation in immunogenicity, and it is still unknown how frequently the general population, let alone those with rheumatic diseases and receiving different immunosuppressive treatments, will need to be revaccinated [53]. Therefore, there is a need to conduct well-designed longitudinal studies to better understand vaccine immunogenicity and to determine the best timing and dosing of COVID-19 vaccines in patients with rheumatic diseases.

LATIN AMERICA

Latin America had some of the world's highest COVID-19 death rates resulting from a combination of factors including political instability, corruption, social unrest, fragile health systems and inequality of income, health and education. For example, 54% of all work carried out in Latin America is informal; such workers have little to no access to health care and often have to work when ill to earn a living. For these individuals, quarantine and social distancing measures were just not possible. Additionally, as the large majority of Latin American countries are lower-middle income, they are often overlooked in global health efforts targeting low-income countries [56]. These disparities disproportionately affect people with chronic diseases, including those with autoimmune diseases who experience barriers within and outside the healthcare system.

Impact on Patients. Low socioeconomic status (SES) has been associated with poorer outcomes, including higher risk of infection, less access to healthcare, and a higher number of comorbidities [57]. In Argentina, Mestizo populations and those cared for in the public health system were more likely to require hospitalization [58]. Additionally, small cities lacked the necessary infrastructure for pandemic management [59]. Informal work is much more common in populations with lower socioeconomic status, and social support for these groups was insufficient [60]. As this population had limited in-person and virtual healthcare access, their diagnosis was usually delayed, portending poorer outcomes [61]. Moreover, social media networks were not helpful vehicles for educational outreach in these populations [62], creating barriers to disseminating COVID-related and other information during the pandemic.

Furthermore, in the PANLAR (Pan American League of Associations for Rheumatology) patient survey study, 23.4% of participants reported discontinuing at least one anti-rheumatic drug. The main reasons included fear that the medication would increase the risk of infection, and economic or administrative issues [63]. However, actual adherence levels may have been even lower, as those with less access to healthcare also had less access to the internet and were less likely to participate in the study. Likewise, another study of physicians reported a 50% reduction in patient adherence to medication [64].

It is important to point out that historically in Latin America there is a high rate of vaccination, particularly in children; this was not the case for COVID-19 where a large percentage of patients with autoimmune diseases said they would decline the vaccine [65]. This lack of confidence could be related to the novelty of the vaccine, or misinformation in the media and/or from political authorities. However, it is important to point out that despite these misgivings, 70% of the Latin American population completed the initial COVID-19 vaccination protocol by May 2022, compared to 58% worldwide [66]. Furthermore, in Latin America individuals with autoimmune disease were prioritized, so they were vaccinated even earlier.

Impact on healthcare providers/practice. One of the main changes during the pandemic was the increased use of telehealth, to which access was unequal. For example, in the PANLAR patient survey, only 32.3% of respondents whose medical appointments were canceled had a telehealth consultation. Among these, 49.9% were completed by telephone calls, and 36.4% by video calls [63]. PANLAR physicians reported the time of face-to-face activity was limited. Telehealth was adopted by 80.0% of rheumatologists, of whom 50.6% used video calls and 45.5% phone calls [64]. The scarcity of video calls impacted the ability of providers to make an accurate diagnosis and treatment plan. Nevertheless, one study demonstrated that in some Latin American settings, telehealth was useful for monitoring patients with stable rheumatoid arthritis [67]. These findings suggested a mixed model could be an option for certain patients, in particular for those who live in rural areas.

Lesson learned. Much work is needed to reduce disparities in Latin America; the outcomes of autoimmune diseases during the pandemic were affected by poverty, healthcare access and health literacy; reducing morbidity from these factors should be the subject of advocacy efforts by rheumatologists and other professionals. Collaborative work between healthcare professionals and patients within the region, and with other regions, should be strongly encouraged to reduce these disparities.

THE UNITED STATES

Individuals with rheumatic diseases faced numerous challenges during the COVID-19 pandemic in the U.S., ranging from disruptions in healthcare and medication access, mental health impacts, and in some cases, more severe outcomes from infection. Furthermore, many rheumatic diseases disproportionately affect individuals with lower SES (e.g., Black, Latino, and Native American), populations in which striking disparities in COVID-19 health outcomes were well-documented.

Impact on Patients. Several studies focused on patients' concerns regarding COVID-19 itself or the relationship between COVID-19 and their underlying rheumatic disease, changes in health-related behaviors during the pandemic, and access to medications and care, including adjustment to telemedicine. COVID-related concerns tended to be higher among patients on biologic DMARDs [68] or JAK inhibitors [69], and were associated with increased social distancing behaviors [69]. Disruptions in medication use and health care visits stemmed from both changes in health-related behaviors (e.g., taking medications as prescribed, going to appointments) and physical barriers to access (e.g., limited supply of medications such as HCQ, shelter-in-place orders), and were associated with increased disease activity and flares [70,71].

While discontinuation of medications was initially associated with concerns regarding vulnerability to COVID-19 or severe outcomes, these concerns improved over the course of 2020. However, a large nation-wide study showed that from Dec 2020 to May 2021, interruptions in DMARD use increased by 80%, and a minority of discontinuations were physician-guided [71]. Concurrently, patients adapted to telemedicine, but generally preferred in-person initial evaluations [72], and older patients were less enthusiastic about virtual appointments. As vaccines became increasingly available in 2021, a desire to return to normal routines promoted uptake, however this was counterbalanced by fears about side effects (including flare of underlying rheumatic disease) or distrust of the vaccines [73].

As early as April 2020, disparities in access and outcomes between white individuals and patients from racial and ethnic minority groups, those with lower SES, or living in rural areas were becoming alarmingly apparent. Among patients with rheumatic diseases, these disparities were pervasive across domains including clinical outcomes, access to care and telemedicine, vaccine uptake, and participation in research, in part due to structural barriers but also in part fueled by mistrust (e.g., mis-information about minorities being targeted as ‘guinea pigs’) [69,74]. For example, two studies from the Global Rheumatology Alliance registry found that patients with rheumatic disease identifying as Black, Latino or Asian had more severe COVID-19 outcomes than whites [75,76].

Impact on Providers/Practices. Rheumatology care delivery during the pandemic became significantly more complex in the setting of competing demands (e.g., diversion of resources to

COVID-19 care), social distancing, obstacles to effective risk communication, and challenges of transitioning rapidly and equitably to virtual care. The American College of Rheumatology developed a series of guidance documents to assist rheumatologists in navigating the pandemic [77]. In addition, three large national studies examined changes in rheumatology practice patterns during the early months of the pandemic [through the Veteran's Administration [78], the American College of Rheumatology RISE registry [79], and the American Arthritis and Rheumatology Associates network [74]]. Rheumatologists in the VA reported comfort managing stable patients using telemedicine, but not new patients or for established patients requiring ongoing therapeutic changes. Providers also perceived potential increases in health care disparities in African Americans, Latino, those in low SES groups, and those living in rural areas [78]. Li et al, compared visit counts from March-August 2020 to the same period in 2019, and found an 11.5% decrease in visits in states with shelter-in-place orders compared with 5.3% in states without. The authors also noted a significant decrease in the proportion of RA patients with disease activity measures documented, which not only impacts patient care but also physician reimbursement [79]. There is little data describing the longitudinal impact that this massive uptake in telemedicine has had on rheumatology practice, patient care-seeking behaviors, and long-term health outcomes.

Lessons Learned. The literature identified several "lessons learned" for rheumatology patients and practice in the U.S. First, early and sustained attention to equity is necessary to protect vulnerable patients during a national health emergency. Rather than reactive policies around drug shortages or unfolding health disparities, proactive measures to ensure access to health care, critical medications and life-saving measures such as PPE and vaccinations would improve outcomes. Misinformation and disinformation presented challenges in the U.S. and often spread to other countries via social media and other online content; misinformation disproportionately impacted vulnerable communities. Efforts to improve health education and public health communication are needed.

CONCLUSIONS

The COVID-19 pandemic has created significant challenges for individuals with rheumatic diseases, particularly vulnerable populations with historically less access to healthcare resources. Disparities in health and healthcare that already existed were augmented, highlighting the need for both local and global responses to address differential outcomes in populations at higher risk of severe COVID-19. Patients across all regions faced disruptions in rheumatology care, drug shortages, and struggles with social isolation and worsening mental health during peak pandemic periods. For providers and health systems, telemedicine capacity and uptake expanded rapidly, and professional societies came together proactively to create guidelines for the management of patients with rheumatic disease during the pandemic, and the efficacy and safety of SARS-CoV2 vaccination. Key lessons learned are illustrated in Table 1, and include:

- Early and authentic attention to disparities in clinical outcomes, health services, and research related to COVID-19, is paramount to ensure equity, even as the acute phase of the pandemic wanes.

- Effective health education and public health communication play critical roles in promoting health-related behaviors and are closely linked with public trust. In many settings, both misinformation and disinformation presented tangible challenges to informed patient decision making during the pandemic and amplified public mistrust.
- Advocacy, in partnership with professional societies and community-based organizations, can help bring about timely and effective policies or regulatory changes to address gaps and inequities in resources (e.g., medication access, PPE) and infrastructure (e.g., telemedicine capacity).
- Well-designed prospective studies are needed to evaluate the long-term impact of the pandemic on health outcomes and health care delivery for patients with rheumatic diseases–particularly those who are most vulnerable.
- Finally, studies are needed to fill gaps in our understanding of SARS-CoV2 vaccine immunogenicity (including ongoing vaccine booster doses) across different regions and vaccine types, and optimal timing and dosing of these COVID-19 vaccines in patients with rheumatic diseases.

ACKNOWLEDGEMENTS

We would like to thank the following individuals for their contributions to the preparation of this manuscript: Shangyi Jin (Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China), Alyssa Grimshaw (Cushing/Whitney Medical Library, Yale University, New Haven, Connecticut, USA), William Odell (Section of Rheumatology, Allergy and Immunology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA),

Bright Katso (Rheumatology Unit, Department of Medicine and Therapeutics,Korle-Bu Teaching Hospita, Accra, Ghana), and Graciela S. Alarcón (Division of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA; Department of Medicine, School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Perú). As part of the literature search process, different strategies were employed in initial scoping of the literature to identify potentially suitable publications for different regions. These approaches included using a large language model (i.e., ChatGPT), using a formal librarian-led search strategy, performing a review of the gray literature, and citation chaining of relevant articles identified. LLM were not used for any other activities related to the preparation and/or synthesis of information for this review.

REFERENCES

1 Mutapi F. *What impact has COVID-19 had across Africa?*. World Economic Forum. 2021. URL: https://www.weforum.org/agenda/2021/10/why-africa-must-gather-its-own-data-to-tackle-the-pandemic/ (Accessed 24 April 2023).

2 Frimpong OB, Bihuzo RM, Commodore R. The COVID-19 Pandemic in Africa: Impact, Responses, and Lessons from Ghana, the Democratic Republic of the Congo, and Rwanda. *Africa Program Occasional Paper* n.d.

3 *COVID-19 and Africa: Socio-economic implications and policy responses*. OECD. n.d. URL: https://www.oecd.org/coronavirus/policy-responses/covid-19-and-africa-socio-economic-implications-and-policy-responses-96e1b282/ (Accessed 24 April 2023).

4 Ziadé N, El Kibbi L, Hmamouchi I, Abdulateef N, Halabi H, Hamdi W, *et al.* Impact of the

COVID-19 pandemic on patients with chronic rheumatic diseases: A study in 15 Arab countries. *Int J Rheum Dis* 2020;**23**:1550–7.

5 Akintayo RO, Akpabio A, Kalla A, Dey D. COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic. *Annals of the* 2021.

6 Ntshalintshali SD, Geldenhuys EM, Moosajee F, Musa WAM, Du Plessis L, Viljoen A, *et al.* Access to chloroquine in patients with rheumatic and musculoskeletal diseases attending rheumatology outpatient clinics during the COVID-19 pandemic. *S Afr Med J* 2021;**111**:720–3.

7 Zomalheto Z, Assogba C, Dossou-yovo H. Impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection and disease-2019 (COVID-19) on the quality of life of rheumatoid arthritis patients in Benin. *The Egyptian Rheumatologist* 2021;**43**:23–7.

8 El Khouly RM, Elsabagh HM, Moawad AAR, Afifi S, Abo El Hawa MA. Functional and mental health affection (depression, anxiety, stress) among Egyptian rheumatic diseases patients during COVID-19 pandemic. *Eur Rev Med Pharmacol Sci* 2022;**26**:4477–85.

9 Ziadé N, Hmamouchi I, El Kibbi L, Abdulateef N, Halabi H, Abutiban F, *et al.* The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. *Clin Rheumatol* 2020;**39**:3205–13.

10 Akintayo RO, Akpabio AA, Kalla AA, Dey D, Migowa AN, Olaosebikan H, *et al.* The impact of COVID-19 on rheumatology practice across Africa. *Rheumatology* 2021;**60**:392–8.

11 Akintayo RO, Bahiri R, El Miedany Y, Olaosebikan H, Kalla AA, Adebajo AO, *et al.* African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. *Clin Rheumatol* 2021;**40**:3445–54.

12 Akintayo RO, Kalla A, Adebajo A. COVID-19 and African rheumatology: progress in adversity. *Lancet Rheumatol* 2020;**2**:e732–4.

13 *COVID 19 Vaccine Perceptions: A 15 country study*. Africa CDC. Africa Centres for Disease Control and Prevention; 2021. URL: https://africacdc.org/download/covid-19-vaccine-perceptions-a-15-country-study/ (Accessed 28 April 2023).

14 *COVID-19 Vaccine Rollout Strategy FAQ*. NICD. 2021. URL: https://www.nicd.ac.za/covid-19-vaccine-rollout-strategy-faq/ (Accessed 28 April 2023).

15 *General FAQs - NPHCDA*. NPHCDA -. NPHCDA; 2022. URL: https://nphcda.gov.ng/general-faqs/ (Accessed 28 April 2023).

16 Omran EA, Habashy RE, Ezz Elarab LA, Hashish MH, El-Barrawy MA, Abdelwahab IA, *et al.* Anti-Spike and Neutralizing Antibodies after Two Doses of COVID-19 Sinopharm/BIBP Vaccine. *Vaccines (Basel)* 2022;**10.**: https://doi.org/10.3390/vaccines10081340.

17 Ben Houmich T, Tali A, Debbagh F, Lamrani Hanchi A, Soraa N. Seroprevalence of SARS-CoV-2 antibodies in vaccinated healthcare workers in Marrakech (Morocco). *Int J Immunopathol Pharmacol* 2022;**36**:3946320221133697.

18 Qi G, Wang H, Guo Y, Peng C, Zhang C, Chen T, *et al.* Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China. *Clin Rheumatol* 2022;**41**:1899–910.

19 Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, *et al.* Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. *Ann Rheum Dis* 2020;**79**:1007–13.

20 Zhao J, Pang R, Wu J, Guo Y, Yang Y, Zhang L, *et al.* Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot'versus in US 'hot spot':

similarities and differences. *Ann Rheum Dis* 2021;**80**:e63–e63.

21 Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, *et al.* COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. *Lancet Rheumatol* 2020;**2**:e557–64.

22 Zhao Y, Du J, Li Z, Xu Z, Wu Y, Duan W, *et al.* It is time to improve the acceptance of COVID-19 vaccines among people with chronic diseases: A systematic review and meta-analysis. *J Med Virol* 2023;**95**:e28509.

23 Tam L-S, Tanaka Y, Handa R, Li Z, Lorenzo JP, Louthrenoo W, *et al.* Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. *Int J Rheum Dis* 2021;**24**:733–45.

24 Su Z, Cheshmehzangi A, McDonnell D, Ahmad J, Šegalo S, Xiang Y-T, *et al.* The Advantages of the Zero-COVID-19 Strategy. *Int J Environ Res Public Health* 2022;**19.**: https://doi.org/10.3390/ijerph19148767.

25 Ahmed S, Grainger R, Santosa A, Adnan A, Alnaqbi KA, Chen Y-H, *et al.* APLAR recommendations on the practice of telemedicine in rheumatology. *Int J Rheum Dis* 2022;**25**:247–58.

26 Zhang Y, Wang J, Zhao L, Xiao J, Shi Z. Online management of rheumatoid arthritis during COVID-19 pandemic. *Ann Rheum Dis* 2021:e4.

27 Zeng H, Liu H, Liu Z, Zhou X, Lu X, Yan Z, *et al.* Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study. *Hum Vaccin Immunother* 2022;**18**:2090176.

28 Fan Y, Geng Y, Wang Y, Deng X, Li G, Zhao J, *et al.* Safety and disease flare of autoimmune

inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. *Ann Rheum Dis* 2022;**81**:443–5.

29 Yi Z, Yao Z, Xu D, Xu C, Fang W, Guo Z, *et al.* Attitudes toward COVID-19 Vaccination: A Survey of Chinese Patients with Rheumatic Diseases. *Vaccines (Basel)* 2022;**10.**: https://doi.org/10.3390/vaccines10101604.

30 Shen M, Dong L, Li M, Zhao Y, Zeng X, Chinese Rheumatology Association. Recommendations on SARS-CoV-2 vaccination in adult patients with rheumatic diseases. *Rheumatol Immunol Res* 2021;**2**:213–6.

31 Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Rheumatology, Chinese Medical Association, Taisheng L, Yan Z. Expert recommendation on severe acute respiratory syndrome Coronavirus 2 vaccination in patients with chronic liver diseases, tuberculosis or rheumatoid diseases. *Infectious Diseases & Immunity* 2021;**1**:137–43.

32 Wilson N, Grout L, Summers JA, Nghiem N, Baker MG. Use of the elimination strategy in response to the COVID-19 pandemic: Health and economic impacts for New Zealand relative to other OECD countries. *bioRxiv* 2021. https://doi.org/10.1101/2021.06.25.21259556.

33 Stobart A, Duckett S. Australia's Response to COVID-19. *Health Econ Policy Law* 2022;**17**:95–106.

34 Basseal JM, Bennett CM, Collignon P, Currie BJ, Durrheim DN, Leask J, *et al.* Key lessons from the COVID-19 public health response in Australia. *Lancet Reg Health West Pac* 2023;**30**:100616.

35 Cai K, He J, Wong PK, Manolios N. The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia. *Eur J Rheumatol Inflamm* 2020;**7**:S91–3.

36 Oh Y, Hennessey A, Young L, Barrett C. Evaluation of patient satisfaction for telehealth (telephone and video) in rheumatology outpatients during COVID-19 pandemic. *Intern Med J* 2022;**52**:559–65.

37 Rischin A, Liew D, Black R, Fletcher A, Buchbinder R, Lassere M, *et al.* Healthcare access and attitudes towards telehealth during the early phase of the COVID-19 pandemic among an Australian cohort with inflammatory arthritis. *Intern Med J* 2021;**51**:788–92.

38 Jefferies S, French N, Gilkison C, Graham G, Hope V, Marshall J, *et al.* COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. *Lancet Public Health* 2020;**5**:e612–23.

39 Sonder GJ, Grey C, Anglemyer A, Tukuitonga C, Hill PC, Sporle A, *et al.* The August 2020 COVID-19 outbreak in Aotearoa, New Zealand: Delayed contact tracing for Pacific people contributes to widening health disparities. *IJID Reg* 2023;**6**:177–83.

40 Mair J, Woolley M, Grainger R. Abrupt change to telephone follow-up clinics in a regional rheumatology service during COVID-19: analysis of treatment decisions. *Intern Med J* 2021;**51**:960–4.

41 Zhu W, De Silva T, Eades L, Morton S, Ayoub S, Morand E, *et al.* The impact of telerheumatology and COVID-19 on outcomes in a tertiary rheumatology service: a retrospective audit. *Rheumatology* 2021;**60**:3478–80.

42 Roberts LJ, Lamont EG, Lim I, Sabesan S, Barrett C. Telerheumatology: an idea whose time

has come. *Intern Med J* 2012;**42**:1072–8.

43 Jhaveri D, Emeto TI, Alele FO, Strom A, Benham H. Use of telemedicine for rheumatology practice in Queensland, Australia: experiences before and during the COVID-19 pandemic. *Intern Med J* 2022;**52**:1685–90.

44 Lim I. Private Practice and Telerheumatology. In: Peoples C, editor. *Telerheumatology: Origins, Current Practice, and Future Directions*. Cham: Springer International Publishing; 2022. p. 281–9.

45 Garrido-Cumbrera M, Marzo-Ortega H, Christen L, Plazuelo-Ramos P, Webb D, Jacklin C, *et al.* Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). *RMD Open* 2021;**7.**: https://doi.org/10.1136/rmdopen-2020-001546.

46 *The continuing impact of COVID-19 on health and inequalities*. The Health Foundation. n.d. URL: https://www.health.org.uk/publications/long-reads/the-continuing-impact-of-covid-19-on-health-and-inequalities (Accessed 28 April 2023).

47 Dejaco C, Alunno A, Bijlsma JW, Boonen A, Combe B, Finckh A, *et al.* Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. *Ann Rheum Dis* 2021;**80**:518–26.

48 Machado PM, Verschueren P, Grainger R, Jones H, Piercy J, van Beneden K, *et al.* Impact of COVID-19 pandemic on the management of patients with RA: a survey of rheumatologists in six European countries. *Rheumatol Adv Pract* 2023;**7**:rkac108.

49 Young K, Yeoh S-A, Putman M, Sattui S, Conway R, Graef E, *et al.* The impact of COVID-19 on

rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey. *Rheumatol Adv Pract* 2022;**6**:rkac001.

50 Mitchell EJ, Ahmed K, Breeman S, Cotton S, Constable L, Ferry G, *et al.* It is unprecedented: trial management during the COVID-19 pandemic and beyond. *Trials* 2020;**21**:784.

51 Mirza M, Siebert S, Pratt A, Insch E, McIntosh F, Paton J, *et al.* Impact of the COVID-19 pandemic on recruitment to clinical research studies in rheumatology. *Musculoskeletal Care* 2022;**20**:209–13.

52 Bijlsma JW, EULAR COVID-19 Task Force. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients' questions. *Ann Rheum Dis* 2022;**81**:786–8.

53 Kroon FPB, Najm A, Alunno A, Schoones JW, Landewé RBM, Machado PM, *et al.* Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. *Ann Rheum Dis* 2022;**81**:422–32.

54 Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, *et al.* EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. *Ann Rheum Dis* 2020;**79**:851–8.

55 Landewé RBM, Kroon FPB, Alunno A, Najm A, Bijlsma JW, Burmester G-RR, *et al.* EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. *Ann Rheum Dis* 2022;**81**:1628–39.

56 The Lancet. COVID-19 in Latin America: a humanitarian crisis. *Lancet* 2020;**396**:1463.

57 Elera-Fitzcarrald C, Ugarte-Gil MF, Alarcón GS. COVID-19 and Its Potential Effect on Patients With Rheumatic Diseases in Latin America. *J Clin Rheumatol* 2020;**26**:215–7.

58 Isnardi CA, Roberts K, Saurit V, Petkovic I, Báez RM, Quintana R, *et al.* Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry. *Clin Rheumatol* 2023;**42**:563–78.

59 Andrus JK, Evans-Gilbert T, Santos JI, Guzman MG, Rosenthal PJ, Toscano C, *et al.* Perspectives on Battling COVID-19 in Countries of Latin America and the Caribbean. *Am J Trop Med Hyg* 2020;**103**:593–6.

60 Busso M, Camacho J, Messina J, Montenegro G. Social protection and informality in Latin America during the COVID-19 pandemic. *PLoS One* 2021;**16**:e0259050.

61 Gamboa-Cárdenas R-V, Barzola-Cerrón S, Toledo-Neira D, Reátegui-Sokolova C, Pimentel-Quiroz V, Zevallos-Miranda F, *et al.* Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. *Clin Rheumatol* 2021;**40**:4725–34.

62 Quintana R, Fernandez S, Guggia L, Fay M, Camacho C, Gomez G, *et al.* Social networks as education strategies for indigenous patients with rheumatoid arthritis during COVID-19 pandemic. Are they useful? *Clin Rheumatol* 2022;**41**:3313–8.

63 Fernández-Ávila DG, Barahona-Correa J, Romero-Alvernia D, Kowalski S, Sapag A, Cachafeiro-Vilar A, *et al.* Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. *Rheumatol Int* 2022;**42**:41–9.

64 Fernández-Ávila DG, Barahona-Correa J, Romero-Alvernia D, Kowalski S, Sapag A, Cachafeiro-Vilar A, *et al.* Impact of COVID-19 Pandemic on Rheumatology Practice in Latin

America. *J Rheumatol* 2021;**48**:1616–22.

65 Felten R, Dubois M, Ugarte-Gil MF, Chaudier A, Kawka L, Bergier H, *et al.* Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases. *Rheumatology* 2021;**60**:SI68–76.

66 Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, *et al.* Coronavirus Pandemic (COVID-19). *Our World in Data* 2020.

67 Santos-Moreno P, Rodríguez-Vargas G-S, Casanova R, Rubio-Rubio J-A, Chávez-Chávez J, Rivera-Triana DP, *et al.* Evaluation of a Non-Face-to-Face Multidisciplinary Health Care Model in a Population with Rheumatoid Arthritis Vulnerable to COVID-19 in a Health Emergency Situation. *Healthcare (Basel)* 2021;**9.**: https://doi.org/10.3390/healthcare9121744.

68 George MD, Venkatachalam S, Banerjee S, Baker JF, Merkel PA, Gavigan K, *et al.* Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. *J Rheumatol* 2021;**48**:603–7.

69 George MD, Baker JF, Banerjee S, Busch H, Curtis D, Danila MI, *et al.* Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. *ACR Open Rheumatol* 2021;**3**:381–9.

70 Maldonado D, Tu E, Mahmood SN, Wahezi DM, Darapaneni R, Sima N, *et al.* Association of Medication Access Difficulty and COVID-19-Related Distress With Disease Flares in Rheumatology Patients During the COVID-19 Pandemic. *Arthritis Care Res* 2021;**73**:1162–70.

71 Dharia T, Venkatachalam S, Baker JF, Banerjee S, Curtis D, Danila MI, *et al.* Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. *Arthritis Care Res* 2022;**74**:733–40.

72 Mortezavi M, Lokineni S, Garg M, Chen YL, Ramsey A. Rheumatology Patient Satisfaction With Telemedicine During the COVID-19 Pandemic in the United States. *J Patient Exp* 2021;**8**:23743735211008825.

73 Shaw YP, Hustek S, Nguyen N, Starlin M, Wipfler K, Wallace BI, *et al.* Rheumatic disease patient decision-making about COVID-19 vaccination: a qualitative analysis. *BMC Rheumatol* 2022;**6**:76.

74 George MD, Danila MI, Watrous D, Reddy S, Alper J, Xie F, *et al.* Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network. *Arthritis Care Res* 2021;**73**:1153–61.

75 Gianfrancesco MA, Leykina LA, Izadi Z, Taylor T, Sparks JA, Harrison C, *et al.* Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. *Arthritis Rheumatol* 2021;**73**:374–80.

76 Ugarte-Gil MF, Alarcón GS, Seet AM, Izadi Z, Montgomery AD, Duarte-García A, *et al.* Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance. *Arthritis Care Res* 2023;**75**:53–60.

77 Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, *et al.* American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic

and Musculoskeletal Diseases: Version 4. *Arthritis Rheumatol* 2022;**74**:e21–36.

78 Singh JA, Richards JS, Chang E, Joseph A, Ng B. Management of Rheumatic Diseases During the COVID-19 Pandemic: A National Veterans Affairs Survey of Rheumatologists. *Arthritis Care Res* 2021;**73**:998–1003.

79 Li J, Ringold S, Curtis JR, Michaud K, Johansson T, Yun H, *et al.* Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. *Rheumatol Int* 2021;**41**:1755–61.

Table 1. Global Lessons Learned from the Impact of COVID-19 on People with Rheumatic Disease and Rheumatology Practices

	Major Challenges	Lessons Learned
People with Rheumatic Disease	Increased risk of infection	Clear public health messaging about wearing masks, social distancing, maintaining or adjusting immunosuppressive medications, and vaccination can help protect vulnerable people with rheumatic diseases
	Mental health concerns	Resources to address social isolation, anxiety and depression put into place as early as possible
	Health equity	Improve access to care and target outreach to patients with rheumatic disease from vulnerable communities regarding vaccination and other preventive strategies
Rheumatology Practices	Disruptions in access to care	Telemedicine serves as a useful tool to improve access to care globally

	Medication supply interruptions	Collaborative efforts by rheumatologists, government agencies, pharmacies and insurance
		companies needed to ensure a stable drug supply for patients with rheumatic diseases
	Health communication	Rheumatologists play a crucial role in providing clear and culturally sensitive communication to ensure that patients know how to protect themselves Rheumatology professional society guidelines can serve as one tool to combat misinformation during public health emergencies Coordination of public health messaging to the rheumatic disease community across organizations is needed to increase the impact of public health messaging